The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.

Viking Therapeutics has initiated a ~280-patient phase 2a study of oral VK2735, with management guiding for a result in H2'25. Previous trials of VK2735 have enrolled ahead of schedule ...

Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy. Viking Therapeutics has signed a long-term ...

The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.

Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...